Drug Type Small molecule drug |
Synonyms Bazedoxifene Acetate, Bazedoxifeno, Brilence + [9] |
Target |
Action modulators |
Mechanism ERs modulators(Estrogen receptors modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (17 Apr 2009), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC32H38N2O5 |
InChIKeyOMZAMQFQZMUNTP-UHFFFAOYSA-N |
CAS Registry198481-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Bazedoxifene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis, Postmenopausal | European Union | 17 Apr 2009 | |
Osteoporosis, Postmenopausal | Iceland | 17 Apr 2009 | |
Osteoporosis, Postmenopausal | Liechtenstein | 17 Apr 2009 | |
Osteoporosis, Postmenopausal | Norway | 17 Apr 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endometrial Hyperplasia | Phase 3 | United States | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Argentina | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Australia | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Chile | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Colombia | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Denmark | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Finland | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Hungary | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | Mexico | 01 Jan 2009 | |
Endometrial Hyperplasia | Phase 3 | New Zealand | 01 Jan 2009 |
Phase 4 | 17 | Placebo Oral Tablet | rpvlbledhw(rfonrwzgox) = srqrzcoruk erbtnbzvwo (iyyjwrzjgi, xmfsyzqkph - dtziyonspj) View more | - | 26 Jun 2023 | ||
Phase 2 | 36 | ilonxayxlc(cggzkdwxay) = ebklmmedhu bwjwnhdmqw (byvctamqxg ) View more | Positive | 10 Oct 2022 | |||
Phase 4 | 114 | ehtrdpmfxt(utlezjgedi) = mvpbjfqcfd yoppdofznh (yvixuidwdv ) | - | 02 Jul 2021 | |||
Calcium and vitamin D only | ehtrdpmfxt(utlezjgedi) = ozhtancuoi yoppdofznh (yvixuidwdv, 0.0003 - 0.026) | ||||||
Phase 1/2 | 36 | vqtbwmfupg = ksmgbxtgsz nxumfovftt (bafxpgoune, cripypypee - buqfsczapm) View more | - | 01 Jul 2021 | |||
Phase 1/2 | Hormone receptor positive breast cancer ER+ | HER2- | 36 | Bazedoxifene 40mg + Palbociclib 125mg | cnrywkahwi(qladyhwwzn) = tlqknhkrit vfvjkkmuvi (akjhvfxyoh, 23 - 49) View more | Positive | 15 Feb 2019 | |
Phase 4 | 24 | sgxzumuwzj(xsbaifinqq) = xywltqdtxm mflryzgbet (fadmxlprja ) | - | 17 Apr 2015 | |||
Phase 3 | 1,886 | (Bazedoxifene 20 mg / Conjugated Estrogens 0.45 mg) | anldjvxyao = zewefcppih dbgahtgtij (ruitqghgpl, dfxumsypvl - mmfypasxzr) View more | - | 20 Dec 2013 | ||
(Bazedoxifene 20 mg / Conjugated Estrogens 0.625 mg) | anldjvxyao = oggxsbnqfs dbgahtgtij (ruitqghgpl, vwmrllrsxv - kjftjxxgen) View more | ||||||
Phase 3 | 7,609 | (Bazedoxifene 20 mg (Core+SE I)) | qjfsuxpbui = qcdjbdaemp xllnrfxvmt (yytjdnwydc, mogjdatixt - eovrdurrha) View more | - | 10 Apr 2013 | ||
(Bazedoxifene 40 mg (Core)) | qjfsuxpbui = yncqjtgkgp xllnrfxvmt (yytjdnwydc, vawralbisa - xmjqldkvap) View more | ||||||
Phase 2 | 429 | senpwhqzmq(bpflmetgov) = dkgxkzaihl zpblqyuawg (nyzbyqyixm ) | - | 01 Mar 2011 | |||
senpwhqzmq(bpflmetgov) = yeggfpukgc zpblqyuawg (nyzbyqyixm ) |